Mentice AB (publ) (MNTC) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome, Frans and Ulrike. Thank you, Richard. Thanks for having us. So, the scene is yours. Thank you, Richard. So, we were going to present the Q2 interim report, which we have, and the earnings call today. So, myself, Frans Venker, together with Ulrike Drots, our CFO for Mantis. And what we have today is first of all highlights in an overview which I will present, the financial results by Ulrica. I have some concluding remarks and then we have questions and answers effectively what we see. So what we see is overall key strategic measures that we implemented within the MENTUS organization. In a cautious market. And so we had net sales of 63 million. And what we saw is that the rolling 12 months net sales came out at 261 compared to 281 last year, of the last quarter, which is 7% lower than effectively the previous quarter on a rolling 12 months. Order intake, 57.5 million, also rolling 12 months down 3%, due to primarily weaker demand in APAC. And that's also what we see, is flat sales activities across EMEA and Americas. We see the order intake growing in EMEA and Americas, but APAC is where we see weaker demand, and that is primarily also due to the lumpiness of the business but also the development that we need to do with the medical device industry in order to capture that growth overall we saw we had fda approve of clearance but also brazilian clearance for our new release of ankiras And that is really advancing our product offering across those markets. And also what we see is that we are tracking towards the business case that we had when we implemented this also as an acquisition for Ankyras. And we're tracking well in that and also are discussing also with other companies, medical device industry companies, in order to sign up towards Ankyros and make them...